These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20541381)

  • 1. Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Verkindre C; Fukuchi Y; Flémale A; Takeda A; Overend T; Prasad N; Dolker M
    Respir Med; 2010 Oct; 104(10):1482-9. PubMed ID: 20541381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.
    Fogarty C; Hattersley H; Di Scala L; Drollmann A
    Respir Med; 2011 Mar; 105(3):337-42. PubMed ID: 21144724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients.
    Vogelmeier C; Verkindre C; Cheung D; Galdiz JB; Güçlü SZ; Spangenthal S; Overend T; Henley M; Mizutani G; Zeldin RK
    Pulm Pharmacol Ther; 2010 Oct; 23(5):438-44. PubMed ID: 20416390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
    Keam SJ; Keating GM
    Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
    Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E
    Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD.
    Donohue JF; Anzueto A; Brooks J; Mehta R; Kalberg C; Crater G
    Respir Med; 2012 Jul; 106(7):970-9. PubMed ID: 22498110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
    Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial.
    Beeh KM; Singh D; Di Scala L; Drollmann A
    Int J Chron Obstruct Pulmon Dis; 2012; 7():503-13. PubMed ID: 22973092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
    Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study.
    Kerwin E; Hébert J; Gallagher N; Martin C; Overend T; Alagappan VK; Lu Y; Banerji D
    Eur Respir J; 2012 Nov; 40(5):1106-14. PubMed ID: 23060624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
    Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
    COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease.
    Littner MR; Ilowite JS; Tashkin DP; Friedman M; Serby CW; Menjoge SS; Witek TJ
    Am J Respir Crit Care Med; 2000 Apr; 161(4 Pt 1):1136-42. PubMed ID: 10764302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of dual therapy with GSK233705 and salmeterol versus monotherapy with salmeterol, tiotropium, or placebo in a crossover pilot study in partially reversible COPD patients.
    Beier J; van Noord J; Deans A; Brooks J; Maden C; Baggen S; Mehta R; Cahn A
    Int J Chron Obstruct Pulmon Dis; 2012; 7():153-64. PubMed ID: 22419863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tiotropium administered by a pressurized metered dose inhaler (pMDI) and spacer produces a similar bronchodilator response as that administered by a Rotahaler in adult subjects with stable moderate-to-severe COPD.
    Brashier B; Dhembare P; Jantikar A; Mahadik P; Gokhale P; Gogtay JA; Salvi SS
    Respir Med; 2007 Dec; 101(12):2464-71. PubMed ID: 17719763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.
    Bateman ED; Tashkin D; Siafakas N; Dahl R; Towse L; Massey D; Pavia D; Zhong NS
    Respir Med; 2010 Oct; 104(10):1460-72. PubMed ID: 20620037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of the long-acting muscarinic antagonist GSK233705 delivered once daily in patients with COPD.
    Bateman E; Feldman G; Kilbride S; Brooks J; Mehta R; Harris S; Maden C; Crater G
    Clin Respir J; 2012 Oct; 6(4):248-57. PubMed ID: 22329914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
    Van de Maele B; Fabbri LM; Martin C; Horton R; Dolker M; Overend T
    COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial.
    D'Urzo A; Ferguson GT; van Noord JA; Hirata K; Martin C; Horton R; Lu Y; Banerji D; Overend T
    Respir Res; 2011 Dec; 12(1):156. PubMed ID: 22151296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.